Payment overview · 2025
General Payments
$780.44
41 reported records · 17 companies
Healthcare provider profile · identity verified
Joel J Johnson, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · PARK RIVER, ND · NPI 1528138542
Verified facts
What the public records show
CMS Open Payments records show Joel J Johnson, M.D. received $780.44 in general payments during 2025 across 41 reported records.
Amgen Inc. accounted for 26.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 22 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 46 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Vraylar by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 55 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Farxiga by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Trulicity by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 385 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Amgen Inc. | Unresolved — no canonical attribution shown | $206.44 | 26.4% | 11 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $117.79 | 15.1% | 6 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $60.38 | 7.7% | 4 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $44.59 | 5.7% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $44.53 | 5.7% | 2 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $37.91 | 4.9% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $35.36 | 4.5% | 2 | 2025 |
| Verona Pharma, Inc. | Unresolved — no canonical attribution shown | $35.26 | 4.5% | 2 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $33.45 | 4.3% | 2 | 2025 |
| Mallinckrodt Hospital Products Inc. | Unresolved — no canonical attribution shown | $27.55 | 3.5% | 1 | 2025 |
| Regeneron Healthcare Solutions, Inc. | Unresolved — no canonical attribution shown | $26.58 | 3.4% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $23.01 | 3.0% | 1 | 2025 |
| GENZYME CORPORATION | Unresolved — no canonical attribution shown | $19.54 | 2.5% | 1 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $18.22 | 2.3% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $17.40 | 2.2% | 1 | 2025 |
| Alkermes, Inc. | Unresolved — no canonical attribution shown | $16.73 | 2.1% | 1 | 2025 |
| KYOWA KIRIN, INC. | Unresolved — no canonical attribution shown | $15.70 | 2.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $780.44 | 41 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $158.65 | 8 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $158.65 | 8 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $117.79 | 6 | 2025 |
Source payment records
|
|||||
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $60.38 | 4 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $47.79 | 3 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $47.79 | 3 | 2025 |
Source payment records
|
|||||
| DUPIXENT Normalized: dupixent |
Biological | GENZYME CORPORATION, Regeneron Healthcare Solutions, Inc. | $46.12 | 2 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $44.59 | 2 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $44.53 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $44.53 | 2 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $37.91 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $35.36 | 2 | 2025 |
Source payment records
|
|||||
| Ohtuvayre Normalized: ohtuvayre |
Drug | Verona Pharma, Inc. | $35.26 | 2 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $33.45 | 2 | 2025 |
Source payment records
|
|||||
| ACTHAR Normalized: acthar |
Biological | Mallinckrodt Hospital Products Inc. | $27.55 | 1 | 2025 |
Source payment records
|
|||||
| LILETTA Normalized: liletta |
Drug | ABBVIE INC. | $23.01 | 1 | 2025 |
Source payment records
|
|||||
| WATCHMAN Access System Normalized: watchman access system |
Device | Boston Scientific Corporation | $18.22 | 1 | 2025 |
Source payment records
|
|||||
| SAPHNELO Normalized: saphnelo |
Biological | AstraZeneca Pharmaceuticals LP | $17.40 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $17.23 | 1 | 2025 |
Source payment records
|
|||||
| ARISTADA Normalized: aristada |
Drug | Alkermes, Inc. | $16.73 | 1 | 2025 |
Source payment records
|
|||||
| LYBALVI Normalized: lybalvi |
Drug | Alkermes, Inc. | $16.73 | 1 | 2025 |
Source payment records
|
|||||
| CRYSVITA Normalized: crysvita |
Drug | KYOWA KIRIN, INC. | $15.70 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 385 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
46 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
55 | 11 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
385 | 58 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1170 | 230 |
| Amlodipine Besylate | Amlodipine Besylate | 897 | 176 |
| Levothyroxine Sodium | Levothyroxine Sodium | 767 | 106 |
| Metoprolol Succinate | Metoprolol Succinate | 712 | 132 |
| Pantoprazole Sodium | Pantoprazole Sodium | 640 | 93 |
| Losartan Potassium | Losartan Potassium | 572 | 116 |
| Omeprazole | Omeprazole | 495 | 90 |
| Tamsulosin Hcl | Tamsulosin Hcl | 450 | 93 |
| Potassium Chloride | Potassium Chloride | 437 | 70 |
| Furosemide | Furosemide | 436 | 86 |
| Sertraline Hcl | Sertraline Hcl | 417 | 61 |
| Eliquis | Apixaban | 385 | 58 |
| Gabapentin | Gabapentin | 380 | 68 |
| Metformin Hcl | Metformin Hcl | 355 | 72 |
| Tramadol Hcl | Tramadol Hcl | 353 | 82 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 345 | 58 |
| Simvastatin | Simvastatin | 328 | 56 |
| Enalapril Maleate | Enalapril Maleate | 312 | 64 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 304 | 39 |
| Metformin Hcl Er | Metformin Hcl | 289 | 54 |
| Metoprolol Tartrate | Metoprolol Tartrate | 279 | 46 |
| Chlorthalidone | Chlorthalidone | 254 | 50 |
| Lisinopril | Lisinopril | 253 | 56 |
| Prednisone | Prednisone | 247 | 122 |
| Trazodone Hcl | Trazodone Hcl | 245 | 46 |
| Lorazepam | Lorazepam | 240 | 53 |
| Clopidogrel | Clopidogrel Bisulfate | 216 | 44 |
| Glipizide Er | Glipizide | 213 | 40 |
| Oxycodone Hcl | Oxycodone Hcl | 194 | 27 |
| Hydrochlorothiazide | Hydrochlorothiazide | 177 | 42 |
| Mirtazapine | Mirtazapine | 170 | 19 |
| Warfarin Sodium | Warfarin Sodium | 168 | 17 |
| Allopurinol | Allopurinol | 159 | 35 |
| Pioglitazone Hcl | Pioglitazone Hcl | 154 | 35 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 141 | 51 |
| Famotidine | Famotidine | 134 | 13 |
| Carvedilol | Carvedilol | 129 | 27 |
| Doxycycline Hyclate | Doxycycline Hyclate | 125 | 88 |
| Cephalexin | Cephalexin | 124 | 75 |
| Clonazepam | Clonazepam | 123 | 15 |
| Duloxetine Hcl | Duloxetine Hcl | 123 | 25 |
| Valsartan | Valsartan | 117 | 29 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 114 | 31 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 113 | 25 |
| Ropinirole Hcl | Ropinirole Hcl | 108 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 106 | 22 |
| Risperidone | Risperidone | 106 | 11 |
| Bumetanide | Bumetanide | 105 | 22 |
| Finasteride | Finasteride | 104 | 19 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 101 | 26 |
| Citalopram Hbr | Citalopram Hydrobromide | 96 | 17 |
| Atenolol | Atenolol | 92 | 13 |
| Levofloxacin | Levofloxacin | 92 | 57 |
| Pravastatin Sodium | Pravastatin Sodium | 90 | 16 |
| Alprazolam | Alprazolam | 89 | 13 |
| Quetiapine Fumarate | Quetiapine Fumarate | 88 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 87 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 86 | 19 |
| Montelukast Sodium | Montelukast Sodium | 85 | 19 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 84 | 17 |
| Nifedipine Er | Nifedipine | 84 | 20 |
| Ozempic | Semaglutide | 83 | 18 |
| Propranolol Hcl | Propranolol Hcl | 82 | 11 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 77 | 20 |
| Bupropion Xl | Bupropion Hcl | 73 | 17 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 73 | 45 |
| Baclofen | Baclofen | 70 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 70 | 13 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 68 | 16 |
| Fluticasone Propionate | Fluticasone Propionate | 66 | 21 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 64 | 20 |
| Cefprozil | Cefprozil | 63 | 52 |
| Oxybutynin Chloride | Oxybutynin Chloride | 63 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 60 | 49 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 58 | 43 |
| Xarelto | Rivaroxaban | 57 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 56 | 12 |
| Klor-Con M20 | Potassium Chloride | 55 | 16 |
| Myrbetriq | Mirabegron | 55 | 11 |
| Novolog Flexpen | Insulin Aspart | 55 | 18 |
| Repatha Sureclick | Evolocumab | 55 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 54 | 12 |
| Fluoxetine Hcl | Fluoxetine Hcl | 53 | 12 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 52 | 18 |
| Levetiracetam | Levetiracetam | 52 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 52 | 13 |
| Spironolactone | Spironolactone | 51 | 15 |
| Memantine Hcl | Memantine Hcl | 50 | suppressed |
| Azithromycin | Azithromycin | 49 | 42 |
| Januvia | Sitagliptin Phosphate | 48 | suppressed |
| Pregabalin | Pregabalin | 46 | suppressed |
| Synthroid | Levothyroxine Sodium | 46 | suppressed |
| Jantoven | Warfarin Sodium | 45 | suppressed |
| Celecoxib | Celecoxib | 43 | suppressed |
| Meloxicam | Meloxicam | 41 | suppressed |
| Metolazone | Metolazone | 41 | 12 |
| Breo Ellipta | Fluticasone/Vilanterol | 40 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 40 | suppressed |
| Fluconazole | Fluconazole | 39 | 21 |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 39 | suppressed |
| Ondansetron Odt | Ondansetron | 37 | 14 |
| Ramipril | Ramipril | 37 | suppressed |
| Calcitriol | Calcitriol | 36 | suppressed |
| Diazepam | Diazepam | 36 | suppressed |
| Digoxin | Digoxin | 36 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 36 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 35 | suppressed |
| Olanzapine | Olanzapine | 35 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 35 | suppressed |
| Easy Touch Pen Needle | Pen Needle, Diabetic | 34 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 34 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 34 | 11 |
| Nitroglycerin | Nitroglycerin | 34 | 29 |
| Dicyclomine Hcl | Dicyclomine Hcl | 33 | suppressed |
| Methotrexate | Methotrexate Sodium | 33 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 33 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 32 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 31 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 30 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 30 | 19 |
| Donepezil Hcl | Donepezil Hcl | 30 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 30 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 30 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 29 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 29 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 28 | suppressed |
| Glimepiride | Glimepiride | 28 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 26 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 26 | suppressed |
| Lamotrigine | Lamotrigine | 26 | suppressed |
| Ranolazine Er | Ranolazine | 26 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 24 | suppressed |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 24 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 23 | suppressed |
| Brilinta | Ticagrelor | 23 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 23 | suppressed |
| Levemir Flexpen | Insulin Detemir | 23 | 12 |
| Ondansetron Hcl | Ondansetron Hcl | 23 | suppressed |
| Ezetimibe | Ezetimibe | 22 | suppressed |
| Praluent Pen | Alirocumab | 22 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 22 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 22 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 21 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 21 | 11 |
| Febuxostat | Febuxostat | 20 | suppressed |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 20 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 19 | suppressed |
| Fentanyl | Fentanyl | 19 | suppressed |
| Sulfasalazine | Sulfasalazine | 19 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 19 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 18 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 18 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 18 | suppressed |
| Leflunomide | Leflunomide | 18 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 18 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 18 | suppressed |
| Effexor Xr | Venlafaxine Hcl | 17 | suppressed |
| Jardiance | Empagliflozin | 17 | suppressed |
| Linzess | Linaclotide | 17 | suppressed |
| Sotalol | Sotalol Hcl | 17 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 16 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 16 | suppressed |
| Hydromorphone Hcl | Hydromorphone Hcl | 16 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 16 | suppressed |
| Metronidazole | Metronidazole | 16 | suppressed |
| Vraylar | Cariprazine Hcl | 16 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 15 | suppressed |
| Primidone | Primidone | 15 | suppressed |
| Amoxicillin | Amoxicillin | 14 | 11 |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 14 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 14 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 14 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 14 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 14 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 14 | suppressed |
| Torsemide | Torsemide | 14 | suppressed |
| Acetazolamide | Acetazolamide | 13 | suppressed |
| Calcium Acetate | Calcium Acetate | 13 | suppressed |
| Clomipramine Hcl | Clomipramine Hcl | 13 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 13 | suppressed |
| Fenofibrate | Fenofibrate | 13 | suppressed |
| Glipizide | Glipizide | 13 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 13 | suppressed |
| Klor-Con M10 | Potassium Chloride | 13 | suppressed |
| Nystop | Nystatin | 13 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 13 | suppressed |
| Trulicity | Dulaglutide | 13 | suppressed |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 13 | suppressed |
| Amiloride-Hydrochlorothiazide | Amiloride/Hydrochlorothiazide | 12 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 12 | suppressed |
| Carbamazepine | Carbamazepine | 12 | suppressed |
| Dulera | Mometasone/Formoterol | 12 | suppressed |
| Estradiol | Estradiol | 12 | suppressed |
| Ezetimibe-Simvastatin | Ezetimibe/Simvastatin | 12 | suppressed |
| Mesalamine | Mesalamine | 12 | suppressed |
| Budesonide | Budesonide | 11 | suppressed |
| Cyltezo(Cf) Pen | Adalimumab-Adbm | 11 | suppressed |
| Dexilant | Dexlansoprazole | 11 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 11 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 11 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 11 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 11 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 11 | suppressed |
| Rybelsus | Semaglutide | 11 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 11 | suppressed |
| Sucralfate | Sucralfate | 11 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $780.44 · 41 records | Amgen Inc. | ACTHAR, ARISTADA, CAPLYTA, CRYSVITA, DUPIXENT, ELIQUIS, EVENITY, INGREZZA, LILETTA, LYBALVI, MOUNJARO, NURTEC ODT, OTEZLA, Ohtuvayre, PROLIA, REPATHA, REXULTI, SAPHNELO, VOQUEZNA, Veozah, WATCHMAN Access System, ZEPBOUND | 9 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error